Neoadjuvant chemotherapy followed by radical vulvectomy for adenoid cystic carcinoma of Bartholin's gland: a case report.
Adenoid cystic carcinoma (ACC)
Bartholin’s gland carcinoma (BGC)
case report
neoadjuvant chemotherapy
Journal
Translational cancer research
ISSN: 2219-6803
Titre abrégé: Transl Cancer Res
Pays: China
ID NLM: 101585958
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
25
11
2021
accepted:
09
08
2022
entrez:
17
11
2022
pubmed:
18
11
2022
medline:
18
11
2022
Statut:
ppublish
Résumé
Adenoid cystic carcinoma (ACC) of the Bartholin's gland is a rare cancer of the female genital tract for which there is no consensus on treatment. As there are no current reports on neoadjuvant chemotherapy followed by surgery for this disease, our case explores the effectiveness of neoadjuvant chemotherapy. We report a case of ACC of Bartholin's gland. The patient is a 69-year-old woman with a left vulvar mass. Pelvic magnetic resonance imaging (MRI) showed a left perineal occupying lesion with indistinct boundaries to the surrounding tissues. The patient received two cycles of neoadjuvant chemotherapy with a regimen of paclitaxel combined with cisplatin and the mass was significantly reduced. Subsequently, she received a radical vulvectomy and left inguinal lymph node dissection. The operation was successful, and the patient was treated with simultaneous radiotherapy and chemotherapy after the surgery. The patient is currently 14 months postoperative and reports no significant pain with normal urination and defecation. The pelvic MRI was reviewed regularly, and there was no sign of recurrence. After neoadjuvant chemotherapy, the extent of the lesion was significantly reduced, which reduced the difficulty of surgery, thus reducing surgical complications and enabling complete resection of the tumor tissue. Based on the treatment of this patient, we speculate that preoperative neoadjuvant chemotherapy may be a better choice for patients with extensive and fixed lesions.
Sections du résumé
Background
UNASSIGNED
Adenoid cystic carcinoma (ACC) of the Bartholin's gland is a rare cancer of the female genital tract for which there is no consensus on treatment. As there are no current reports on neoadjuvant chemotherapy followed by surgery for this disease, our case explores the effectiveness of neoadjuvant chemotherapy.
Case Description
UNASSIGNED
We report a case of ACC of Bartholin's gland. The patient is a 69-year-old woman with a left vulvar mass. Pelvic magnetic resonance imaging (MRI) showed a left perineal occupying lesion with indistinct boundaries to the surrounding tissues. The patient received two cycles of neoadjuvant chemotherapy with a regimen of paclitaxel combined with cisplatin and the mass was significantly reduced. Subsequently, she received a radical vulvectomy and left inguinal lymph node dissection. The operation was successful, and the patient was treated with simultaneous radiotherapy and chemotherapy after the surgery. The patient is currently 14 months postoperative and reports no significant pain with normal urination and defecation. The pelvic MRI was reviewed regularly, and there was no sign of recurrence.
Conclusions
UNASSIGNED
After neoadjuvant chemotherapy, the extent of the lesion was significantly reduced, which reduced the difficulty of surgery, thus reducing surgical complications and enabling complete resection of the tumor tissue. Based on the treatment of this patient, we speculate that preoperative neoadjuvant chemotherapy may be a better choice for patients with extensive and fixed lesions.
Identifiants
pubmed: 36388019
doi: 10.21037/tcr-21-2634
pii: tcr-11-10-3883
pmc: PMC9641131
doi:
Types de publication
Case Reports
Langues
eng
Pagination
3883-3889Informations de copyright
2022 Translational Cancer Research. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tcr.amegroups.com/article/view/10.21037/tcr-21-2634/coif). The authors have no conflicts of interest to declare.
Références
Int J Gynecol Cancer. 2021 Feb;31(2):292-298
pubmed: 33214217
J Surg Oncol. 1985 Oct;30(2):132-7
pubmed: 3001428
J Natl Compr Canc Netw. 2018 May;16(5):479-490
pubmed: 29752322
Gynecol Obstet Invest. 2005;59(1):54-8
pubmed: 15479983
Arch Pathol Lab Med. 2007 May;131(5):796-8
pubmed: 17488169
Am J Obstet Gynecol. 1983 Oct 15;147(4):385-90
pubmed: 6312799
Arch Gynecol Obstet. 2008 Nov;278(5):473-6
pubmed: 18283472
Crit Rev Oncol Hematol. 2017 Sep;117:1-11
pubmed: 28807231
Gynecol Oncol. 2006 Feb;100(2):422-5
pubmed: 16194566
Obstet Gynecol. 1986 Jan;67(1):115-20
pubmed: 2999664
Oncology. 2020;98(8):513-519
pubmed: 32408297
Gynecol Oncol. 1989 Aug;34(2):145-7
pubmed: 2546874
J Int Med Res. 2020 Feb;48(2):300060519863540
pubmed: 31354009
Int J Gynecol Cancer. 2017 May;27(4):832-837
pubmed: 28441255
Taiwan J Obstet Gynecol. 2012 Mar;51(1):119-20
pubmed: 22482984
Eur J Gynaecol Oncol. 2016;37(1):113-6
pubmed: 27048121
Acta Cytol. 1975 Mar-Apr;19(2):152-3
pubmed: 164752
Taiwan J Obstet Gynecol. 2013 Mar;52(1):113-6
pubmed: 23548230
Arch Gynecol Obstet. 2009 May;279(5):747-50
pubmed: 18800221
Int J Gynecol Cancer. 2016 May;26(4):785-9
pubmed: 26844611